Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Jul;6(7):523.
doi: 10.1016/S2468-1253(21)00148-5.

SARS-CoV-2 vaccination for patients with inflammatory bowel disease

Hannah M Garcia Garrido  1 , Martin P Grobusch  1 , Geert R A M D'Haens  2 , Abraham Goorhuis  3
Affiliations
Comment

SARS-CoV-2 vaccination for patients with inflammatory bowel disease

Hannah M Garcia Garrido et al. Lancet Gastroenterol Hepatol. 2021 Jul.
No abstract available

PubMed Disclaimer

Conflict of interest statement

We declare no competing interests.

Comment in

  • SARS-CoV-2 vaccination for patients with inflammatory bowel disease - Authors' reply.
    Alexander JL, Kennedy NA, Lees CW, Ahmad T, Powell N; British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group. Alexander JL, et al. Lancet Gastroenterol Hepatol. 2021 Jul;6(7):523-524. doi: 10.1016/S2468-1253(21)00194-1. Lancet Gastroenterol Hepatol. 2021. PMID: 34119033 Free PMC article. No abstract available.

Comment on

Similar articles

See all similar articles

Cited by

References

    1. Alexander JL, Moran GW, Gaya DR, et al. SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement. Lancet Gastroenterol Hepatol. 2021;6:218–224. - PMC - PubMed
    1. Garcia Garrido HM, Veurink AM, Leeflang M, Spijker R, Goorhuis A, Grobusch MP. Hepatitis A vaccine immunogenicity in patients using immunosuppressive drugs: a systematic review and meta-analysis. Travel Med Infect Dis. 2019;32 - PubMed
    1. van Aalst M, Garcia Garrido HM, van der Leun J, et al. Immunogenicity of the currently recommended pneumococcal vaccination schedule in patients with inflammatory bowel disease. Clin Infect Dis. 2020;70:595–604. - PubMed
    1. van Aalst M, Langedijk AC, Spijker R, de Bree GJ, Grobusch MP, Goorhuis A. The effect of immunosuppressive agents on immunogenicity of pneumococcal vaccination: a systematic review and meta-analysis. Vaccine. 2018;36:5832–5845. - PubMed
    1. Teijaro JR, Farber DL. COVID-19 vaccines: modes of immune activation and future challenges. Nat Rev Immunol. 2021;21:195–197. - PMC - PubMed

Substances